Alterity Therapeutics Limited (NASDAQ:ATHE) Sees Large Decline in Short Interest

Alterity Therapeutics Limited (NASDAQ:ATHE) was the target of a large decline in short interest in November. As of November 30th, there was short interest totalling 2,000 shares, a decline of 45.9% from the November 15th total of 3,700 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average trading volume of 42,700 shares, the days-to-cover ratio is presently 0.0 days.

Alterity Therapeutics Price Performance

Shares of NASDAQ ATHE traded up $0.18 during trading hours on Friday, reaching $2.40. 44,028 shares of the stock were exchanged, compared to its average volume of 50,530. The stock’s fifty day simple moving average is $1.36 and its 200 day simple moving average is $1.51. Alterity Therapeutics has a 52 week low of $1.00 and a 52 week high of $3.25.

Analysts Set New Price Targets

Separately, Maxim Group started coverage on Alterity Therapeutics in a research report on Thursday. They set a “buy” rating and a $8.00 price objective for the company.

Alterity Therapeutics Company Profile

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.